Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $19.6000 (1.03%) ($19.1000 - $19.7000) on Wed. Feb. 20, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 13.06% (three month average) | RSI | 46 | Latest Price | $19.6000(1.03%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TNXP advances 1.3% a day on average for past five trading days. | Weekly Trend | TNXP declines -2.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) SKYY(11%) XBI(11%) IBB(10%) IWM(10%) IWO(10%) | Factors Impacting TNXP price | TNXP will decline at least -6.53% in a week (0% probabilities). BWX(-8%) TLT(-7%) SIL(-7%) SHY(-7%) GLD(-7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -6.53% (StdDev 13.06%) | Hourly BBV | 0 () | Intraday Trend | 2.1% | | | |
|
1 - 5 Day Possible Target | $12.44(-36.53%) | 5 Day Moving Average | $19.14(2.4%) | 10 Day Moving Average | $19.25(1.82%) | 20 Day Moving Average | $19.54(0.31%) | To recent high | -71.9% | To recent low | 7.1% | Market Cap | $5.194b | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |